28.02.2023 - United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s business during a fireside chat session .
United Therapeutics Corporation (NASDAQ:NASDAQ:UTHR) Q3 2022 Earnings Conference Call November 02, 2022 9:00 AM ET Company Participants Dewey Sedman – Head-Investor Relations Martine.
03.08.2022 - United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared .
The FDA has approved Tyvaso DPI (treprostinil) for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability.
United Therapeutics Corporation (NASDAQ:NASDAQ:UTHR) Q1 2022 Results Conference Call May 04, 2022 09:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson,.